A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

NCT07656727 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity and Cardiovascular Risk

Interventions

DRUG: Oral BGE-102
DRUG: Oral Placebo Matching BGE-102

Sponsor

BioAge Labs, Inc.